HCPLive Network

Psoriatic Arthritis

A Phase 3 trial of the monoclonal antibody secukinumab indicates it is an effective treatment for patients with ankylosing spondylitis (AS) incompletely treated by standard therapy, according to data presented at the 2014 American College of Rheumatology meeting.
Rheumatic conditions may have an increased association with adverse cardiovascular events, according to research published in the Annals of Rheumatic Diseases.
The majority of patients with psoriatic arthritis treated with disease-modifying antirheumatic drugs will switch medications, discontinue treatment, or add an additional medicine, usually within a few months of initiating treatment.
Psoriatic arthritis may be difficult to distinguish from other types of arthritis. According to results of a new study, assessing a patient’s sense of balance and hearing ability may be an aid in the diagnosis.
Until apremilast was approved earlier this year, patients with psoriatic arthritis had to rely primarily on injectable therapies, which contributed to less than optimal treatment adherence in many patients.
Patients treated with certolizumab pegol for 24 weeks showed rapid improvement in the signs and symptoms of psoriatic arthritis.
Psoriatic Arthritis Latest News
Psoriatic Arthritis Clinical Trials